Brevan Howard Capital Management LP Nurix Therapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $13.9 Billion
- Q4 2024
A detailed history of Brevan Howard Capital Management LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 21,495 shares of NRIX stock, worth $362,620. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,495Holding current value
$362,620% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$115 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$73.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$70.7 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$65.5 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$60.5 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $795M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...